Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study

NCT04644406 is registered in ClinicalTrials.gov with Hospices Civils de Lyon as lead sponsor.

NCT NCT04644406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04644406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
Lead sponsor
Hospices Civils de Lyon
Phase
Observational
Overall status
Unknown status
Start date
December 31, 2020
Completion date
June 30, 2023
Enrollment
200 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

her-2 positive breast cancer